Catalysts for Sanofi-Aventis US LLC

Rifampin Injection shortage — Sanofi-Aventis U.S. LLC

ADLYXIN (LIXISENATIDE) — FDA approval

SOLIQUA 100/33 (INSULIN GLARGINE) — FDA approval

AUBAGIO (TERIFLUNOMIDE) — FDA approval

PRIMAQUINE (PRIMAQUINE PHOSPHATE) — FDA approval

PRIFTIN (RIFAPENTINE) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFATER (ISONIAZID) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFATER (ISONIAZID) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

ADLYXIN (LIXISENATIDE) — FDA approval

SOLIQUA 100/33 (INSULIN GLARGINE) — FDA approval

PRIMAQUINE (PRIMAQUINE PHOSPHATE) — FDA approval

RIFATER (ISONIAZID) — FDA approval

ADLYXIN (LIXISENATIDE) — FDA approval

SOLIQUA 100/33 (INSULIN GLARGINE) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFATER (ISONIAZID) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

AUBAGIO (TERIFLUNOMIDE) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFATER (ISONIAZID) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

ADLYXIN (LIXISENATIDE) — FDA approval

SOLIQUA 100/33 (INSULIN GLARGINE) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFATER (ISONIAZID) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval